Overview PCSK9 inhibitors are a class of biologic agents (monoclonal antibodies) that block proprotein convertase subtilisin/kexin type 9 (PCSK9) — a circulating protein that promotes degradation of LDL receptors (LDLRs) on the surface of hepatocytes. By inhibiting PCSK9, these drugs prevent…